Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.


Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 2 10 2019
medline: 25 9 2021
entrez: 2 10 2019
Statut: ppublish

Résumé

Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS). To investigate the effectiveness and safety of rituximab in relapsing-remitting (RR) and progressive MS. This is a multicenter, retrospective study on consecutive MS patients treated off-label with rituximab in 22 Italian and 1 Swiss MS centers. Relapse rate, time to first relapse, Expanded Disability Status Scale (EDSS) progression, incidence of adverse events, and radiological outcomes from 2009 to 2019 were analyzed. A total of 355/451 enrolled subjects had at least one follow-up visit and were included in the outcome analysis. Annualized relapse rate significantly decreases after rituximab initiation versus the pre-rituximab start year in RRMS (from 0.86 to 0.09, Consistently with other observational studies, our data show effectiveness of rituximab in reducing disease activity in patients with MS.

Sections du résumé

BACKGROUND
Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS).
OBJECTIVE
To investigate the effectiveness and safety of rituximab in relapsing-remitting (RR) and progressive MS.
METHODS
This is a multicenter, retrospective study on consecutive MS patients treated off-label with rituximab in 22 Italian and 1 Swiss MS centers. Relapse rate, time to first relapse, Expanded Disability Status Scale (EDSS) progression, incidence of adverse events, and radiological outcomes from 2009 to 2019 were analyzed.
RESULTS
A total of 355/451 enrolled subjects had at least one follow-up visit and were included in the outcome analysis. Annualized relapse rate significantly decreases after rituximab initiation versus the pre-rituximab start year in RRMS (from 0.86 to 0.09,
CONCLUSION
Consistently with other observational studies, our data show effectiveness of rituximab in reducing disease activity in patients with MS.

Identifiants

pubmed: 31573386
doi: 10.1177/1352458519872889
doi:

Substances chimiques

Immunologic Factors 0
Rituximab 4F4X42SYQ6

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1519-1531

Auteurs

Chiara Zecca (C)

Neurocentre of Southern Switzerland, Department of Neurology, Ospedale Civico, Lugano, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.

Francesca Bovis (F)

Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.

Giovanni Novi (G)

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Sciences (DINOGMI), University of Genoa, Genoa, Italy/IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Marco Capobianco (M)

SCDO Neurologia e Centro di Riferimento Regionale Sclerosi Multipla, AOU San Luigi, Orbassano, Italy.

Roberta Lanzillo (R)

Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.

Jessica Frau (J)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Anna Maria Repice (AM)

Regional MS Center, Careggi University Hospital, Florence, Italy.

Bahia Hakiki (B)

IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.

Sabrina Realmuto (S)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy/AOOR Villa Sofia-Cervello, Centro di Neuroimmunologia, UOC di Neurologia e Stroke Unit, Palermo, Italy.

Simona Bonavita (S)

Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy.

Erica Curti (E)

Neurosciences Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Laura Brambilla (L)

Department of Neuroimmunology and Neuromuscular Diseases, Foundation IRCCS Neurological Institute Carlo Besta, Milan, Italy.

Giorgia Mataluni (G)

Multiple Sclerosis Unit, Department of System Medicine, University of Rome Tor Vergata, Rome, Italy.

Paola Cavalla (P)

Multiple Sclerosis Center, Department of Neurosciences and Mental Health, City of Health and Science University Hospital of Turin, Turin, Italy.

Alessia Di Sapio (A)

Department of Neurology, Ospedale Regina Montis Regalis-ASLCN1, Mondovì, Italy.

Elisabetta Signoriello (E)

Multiple Sclerosis Center, II Division of Neurology, University of Campania Luigi Vanvitelli, Naples, Italy.

Stefania Barone (S)

Institute of Neurology, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.

Giorgia T Maniscalco (GT)

Neurological Clinic and Multiple Sclerosis Center, "AORN A.Cardarelli," Naples, Italy.

Ilaria Maietta (I)

Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.

Isabella Maraffi (I)

Neurocentre of Southern Switzerland, Department of Neurology, Ospedale Civico, Lugano, Switzerland.

Giacomo Boffa (G)

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Sciences (DINOGMI), University of Genoa, Genoa, Italy/IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Simona Malucchi (S)

SCDO Neurologia e Centro di Riferimento Regionale Sclerosi Multipla, AOU San Luigi, Orbassano, Italy.

Agostino Nozzolillo (A)

Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.

Giancarlo Coghe (G)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Claudia Mechi (C)

Regional MS Center, Careggi University Hospital, Florence, Italy.

Giuseppe Salemi (G)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy.

Antonio Gallo (A)

Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy.

Rosaria Sacco (R)

Neurocentre of Southern Switzerland, Department of Neurology, Ospedale Civico, Lugano, Switzerland.

Maria Cellerino (M)

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Sciences (DINOGMI), University of Genoa, Genoa, Italy/IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Maria Malentacchi (M)

SCDO Neurologia e Centro di Riferimento Regionale Sclerosi Multipla, AOU San Luigi, Orbassano, Italy.

Marcello De Angelis (M)

Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.

Lorena Lorefice (L)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Eliana Magnani (E)

Regional MS Center, Careggi University Hospital, Florence, Italy.

Elio Prestipino (E)

NEUROFARBA, Section Neurosciences, University of Florence, Florence, Italy.

Francesca Sperli (F)

SCDO Neurologia e Centro di Riferimento Regionale Sclerosi Multipla, AOU San Luigi, Orbassano, Italy.

Vincenzo Brescia Morra (V)

Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.

Giuseppe Fenu (G)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Alessandro Barilaro (A)

Regional MS Center, Careggi University Hospital, Florence, Italy.

Gianmarco Abbadessa (G)

Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy.

Alessio Signori (A)

Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.

Franco Granella (F)

Neurosciences Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Maria Pia Amato (MP)

IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy/NEUROFARBA, Section Neurosciences, University of Florence, Florence, Italy.

Antonio Uccelli (A)

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Sciences (DINOGMI), University of Genoa, Genoa, Italy/IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Claudio Gobbi (C)

Neurocentre of Southern Switzerland, Department of Neurology, Ospedale Civico, Lugano, Switzerland.

Maria Pia Sormani (MP)

Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy/IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH